|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.97 - 35.22|
|52 Week Range||34.72 - 44.54|
|PE Ratio (TTM)||33.97|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.01 (5.75%)|
|1y Target Est||43.67|
GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application with the US Food and Drug Administration for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease .
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. ...
Shares of Gilead Sciences (GILD) are higher on Wednesday morning, and RBC Capital Markets' Brian Abrahams thinks they'll keep rising. Abrahams and his team reiterated and Outperform rating and $96 price target on Gilead today, a day after the Food and Drug Administration updated labels for competitor GlaxoSmithKline's (GSK)/ViiV dolutegravir-based HIV treatments to include risk of liver toxicity, even in patients without risk factors, and now recommends monitoring. While that may be unfortunate for patients, it's good news for Gilead, Abrahams writes, given that it makes its products look more competitive. More detail from the note: We see this new AE warning and monitoring requirement for ViiV as a potential long-term advantage to help GILD maintain its HIV leadership.
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
In 3Q17, Merck’s (MRK) Gardasil and Gardasil 9 generated revenue of $675 million, which reflected a ~22% fall YoY (year-over-year) and ~44% growth QoQ (quarter-over-quarter). Lower sales in the US market…...
The green light is a boost for GlaxoSmithKline (GSK.L), whose Chief Executive Emma Walmsley counts the medicine among three products that are "critical" to help fill a revenue gap left by falling sales of the ageing lung drug Advair. The other two are a three-in-one inhaler for chronic lung disease and a shingles vaccine, which were approved in September and October. The new HIV treatment, called Juluca, is a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, and is available to patients who have been on a stable regimen for at least six months.
LONDON , Nov. 21, 2017 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that ...
The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines. The treatment, called Juluca, is a fixed-dose tablet that combines two previously approved drugs, dolutegravir and rilpivirine, and is available to patients who have been on a stable regimen for at least six months. Juluca belongs to GlaxoSmithKline Plc's majority-owned ViiV Healthcare, in which Pfizer Inc and Shionogi also have small stakes.
Let’s talk about the popular GlaxoSmithKline plc (LSE:GSK). The company’s shares saw significant share price volatility over the past couple of months on the LSE, rising to the highs ofRead More...
LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK ) ("GSK"), following ...
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
Europe has approved GlaxoSmithKline's (GSK.L) new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S). The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.
Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis. The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.
The Crown Prince of Abu Dhabi launched a fund with the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis, which leads to a condition known as elephantiasis.
VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...
In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.
All things considered, it can’t be terribly surprising General Electric Company (NYSE:GE) opted to reduce its dividend. The relatively new CEO John Flannery flat-out told shareholders he was mulling the possibility back in October! In no certain order, here’s a closer look at ten more dividend stocks that could soon see a dividend cut of their own.
GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.
A great investment for income investors with a long time horizon is in dividend-paying companies like British American Tobacco. Dividend stocks are a safe bet to increase your portfolio valueRead More...
NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...